Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Inhibition of p300 impairs Foxp3⁺ T regulatory cell function and promotes antitumor immunity.

Nature medicine | 2013

Forkhead box P3 (Foxp3)(+) T regulatory (T(reg)) cells maintain immune homeostasis and limit autoimmunity but can also curtail host immune responses to various types of tumors. Foxp3(+) T(reg) cells are therefore considered promising targets to enhance antitumor immunity, and approaches for their therapeutic modulation are being developed. However, although studies showing that experimentally depleting Foxp3(+) T(reg) cells can enhance antitumor responses provide proof of principle, these studies lack clear translational potential and have various shortcomings. Histone/protein acetyltransferases (HATs) promote chromatin accessibility, gene transcription and the function of multiple transcription factors and nonhistone proteins. We now report that conditional deletion or pharmacologic inhibition of one HAT, p300 (also known as Ep300 or KAT3B), in Foxp3(+) T(reg) cells increased T cell receptor-induced apoptosis in T(reg) cells, impaired T(reg) cell suppressive function and peripheral T(reg) cell induction, and limited tumor growth in immunocompetent but not in immunodeficient mice. Our data thereby demonstrate that p300 is important for Foxp3(+) T(reg) cell function and homeostasis in vivo and in vitro, and identify mechanisms by which appropriate small-molecule inhibitors can diminish T(reg) cell function without overtly impairing T effector cell responses or inducing autoimmunity. Collectively, these data suggest a new approach for cancer immunotherapy.

Pubmed ID: 23955711 RIS Download

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: 1R01CA158941
  • Agency: NCI NIH HHS, United States
    Id: R01 CA158941
  • Agency: NIAID NIH HHS, United States
    Id: P01AI073489
  • Agency: NIAID NIH HHS, United States
    Id: K08AI095353
  • Agency: NCI NIH HHS, United States
    Id: P30 CA021765
  • Agency: NIAID NIH HHS, United States
    Id: P01 AI073489
  • Agency: NIAID NIH HHS, United States
    Id: K08 AI095353

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Applied Biosystems (tool)

RRID:SCR_005039

An Antibody supplier

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

B6.129(Cg)-Foxp3tm4(YFP/icre)Ayr/J (tool)

RRID:IMSR_JAX:016959

Mus musculus with name B6.129(Cg)-Foxp3tm4(YFP/icre)Ayr/J from IMSR.

View all literature mentions

BALB/cAnNCrl (tool)

RRID:MGI:2683685

laboratory mouse with name BALB/cAnNCrl from MGI.

View all literature mentions

HEK293T (tool)

RRID:CVCL_0063

Cell line HEK293T is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

B6D2F1 (tool)

RRID:MGI:5649818

laboratory mouse with name B6D2F1 from MGI.

View all literature mentions